UNSPSC 51292001: Adrafinil

This classification denotes an alpha-adrenergic agonist with the molecular formula C15H15NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BI81Z4542G, chemically known as acetohydroxamic acid, 2-((diphenylmethyl)sulfinyl)- but generally known as adrafinil, which bears US NIH Compound Identifier 3033226. European Medicines Agency schedules Adrafinil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05278MIG. The term ADRAFINIL is an International Non-Proprietary Name.

UNSPSC 51292001 Adrafinil, a Commodity code, shows a significant mismatch between its nominal scope and recent state and local procurement activity. The code is indexed to adrafinil, a wakefulness-promoting pharmaceutical agent, but the single recent opportunity on record — Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026 — solicits naloxone and safe drug deactivation systems for community health support, a product category unrelated to the code's stated classification. This disconnect suggests either a data-entry error in the code assignment or that the code is not actively used for its intended purpose in state and local procurement.

The Seminole County solicitation is an Invitation for Bid with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract carries a two-year initial term with a one-year renewal option, includes a three-month probationary termination clause, and incorporates potential FEMA funding with associated federal compliance requirements. Bidders must meet E-Verify and drug-free workplace certification standards. No other recent opportunities appear under this code, and the geographic footprint is limited to a single Florida county solicitation.